Nanobiotix is trading 5.8% lower at $31.38 in pre-market, with no clear company-specific catalyst identified.
- The company’s latest listed release, dated September 24, reported first-half progress and results; a Q2 earnings preview points to a September 29 report.
- U.S. futures are lower as oil and bond yields rise amid renewed geopolitical and inflation concerns. This may be contributing to pressure, but available evidence does not establish a direct catalyst for Nanobiotix’s decline.